Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.


TSXV:TLT - Post by User

Post by wildbird1on Aug 21, 2022 12:13pm
556 Views
Post# 34910023

Big Pharma & Optimized Patients CR%...

Big Pharma & Optimized Patients CR%...A Big Pharma that will try to strike  a deal with TLT will first ask TLT, what will be the more exact CR% of patients that will be treated with TLT ACT(anti-cancer treatment)?
The answer will be the Optimized Patients CR%.

Let's have a look at the 18 Optimized patients 90 days CR% results.
3Q2021 Newsletter (Nov 29, 2021).
Complete Response(CR)........8 Patients....44%.
Partial Response(PR)..............2      "       ....11%.
Pending ...................................7      "       ....39%.
No Response(NR)....................1      "       ..... 6%.
The 44% CR% is for 18 Patients, in order to have a more accurate CR% you have to substract the 7 Pending patients.
18 patients - 7 Pending patients = 11 patients that have received their 90 days results.
The more appropriate CR% is, 8 CR patients out of 11 patients = 73% CR.
- TLT said " Once a patient has obtained CR(Complete Response) the duration of the response remain fairly the same".
A Big Pharma will have to agree that considering that TLT ACT(Anti-cancer treatment) is treating only patients that have failed all other treatments, anything over 60%CR is huge.

As TLT will polish its treatment protocol, two things will happen.
1) The CR%(73%) will get better & better.
2) In the future , only one treatment could be necessary to achieve a CR(Complete Response), making TLT treatment more affordable.


As a bonus TLT seem to have a good shot at a Universal Covid-19 Vaccine.



<< Previous
Bullboard Posts
Next >>